Histological Analysis of Term Placentas from Hyperimmune Globulin-Treated and Untreated Mothers with Primary Cytomegalovirus Infection

Fetal Diagn Ther. 2019;45(2):111-117. doi: 10.1159/000487302. Epub 2018 Apr 23.

Abstract

Background: The Congenital Human Cytomegalovirus Infection Prevention (CHIP) study, a randomized, blinded, placebo-controlled trial, demonstrated that the efficacy of hyperimmune globulin (HIG) was not different from that of placebo regarding transmission of cytomegalovirus (CMV) from mothers to newborns. Our aim was to analyze histologically HIG effects on placentas collected for the CHIP study.

Materials and methods: Virological and histological analyses were performed on 40 placentas from transmitter and nontransmitter HIG-treated and untreated mothers by assessing the number of CMV-positive cells, tissue viral load, tissue damage, and compensatory mechanisms.

Results: The HIG and placebo groups showed no significant differences in the number of CMV-positive cells (median number in 10 fields at 10 high-power fields: 2.5 vs. 2, p = 0.969) and viral load (median load: 5 copies/5 ng vs. 10.5 copies/5 ng, p = 0.874). Regarding histological examination, the scores of parameters related to tissue damage and hypoxic parenchymal compensation were higher in transmitters except for chorangiosis, with statistically significant differences observed for chronic villitis (p = 0.007), calcification (p = 0.011), and the total score of tissue damage (p < 0.001). The HIG and placebo groups showed no significant differences for all tissue damage and compensation parameters and overall scores.

Discussion: HIGs are not able to reduce placental viral load and histological damage, which was significantly associated only with infection.

Keywords: Immunohistochemistry; Infection; PCR; Placenta; Prenatal treatment.

MeSH terms

  • Cytomegalovirus / immunology
  • Cytomegalovirus Infections / prevention & control
  • Cytomegalovirus Infections / therapy
  • Cytomegalovirus Infections / transmission*
  • Female
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Immunotherapy
  • Infectious Disease Transmission, Vertical / prevention & control
  • Placenta / pathology
  • Placenta / virology*
  • Pregnancy
  • Pregnancy Complications, Infectious / virology*
  • Viral Load

Substances

  • Immunoglobulins, Intravenous
  • cytomegalovirus-specific hyperimmune globulin